Omarigliptin (OMG, Figure 1A), a novel long-acting DPP-4 inhibitor recently approved for the management of T2DM [25], is the only gliptin possessing the ability to cross the blood–brain barrier (BBB) due to its low molecular weight and adequate lipophilic properties [26]. This evidence concerns the gene DPP4 and type 2 diabetes mellitus.